Vericel (VCEL) Interest Coverage Ratio (2010 - 2026)
Vericel (VCEL) posted Interest Coverage Ratio of 0.69 for Q2 2026, up 105.38% sequentially from 12.9 in Q1 2026, and up 121.39% YoY from 0.31 in Q2 2025.
Powered by 
Analysis
Vericel (VCEL) Interest Coverage Ratio (2010 - 2026) Analysis & Trends
Vericel has reported Interest Coverage Ratio for 17 years, with the latest figure at 0.69 in Q2 2026.
- Quarterly Interest Coverage Ratio rose 121.39% year-over-year to 0.69 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 29.18 (up 1428.5% YoY) and the FY2025 annual result came in at 0.27, up 714.92% from the prior year.
- Interest Coverage Ratio advanced to 0.69 in Q2 2026 per VCEL's latest filing, from 12.9 in the prior quarter.
- Over five years, Interest Coverage Ratio peaked at 81.61 in Q4 2023 and troughed at 454.1 in Q2 2022.
- A 5-year average of 46.45 and a median of 3.6 in 2024 frame the typical range for Interest Coverage Ratio.
- The sharpest annual moves came in 2024 and 2025: Interest Coverage Ratio tumbled 25726.97% in 2024, then soared 239.96% in 2025.
- Over 5 years, Interest Coverage Ratio stood at 27.29 in 2022, then jumped by 199.08% to 81.61 in 2023, then sank by 73.04% to 22.0 in 2024, then decreased by 1.27% to 21.72 in 2025, then sank by 96.8% to 0.69 in 2026.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 0.69, 12.9, and 21.72 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -21.24 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.42 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.08 |
| 10 | Vericel | 2.05 Bn | 1.89 Bn | 56.40 Mn | 2.71 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.71 |
| Mar 31, 2026 | -50.40 |
| Dec 31, 2025 | 138.36 |
| Sep 30, 2025 | 21.84 |
| Jun 30, 2025 | -12.92 |
| Mar 31, 2025 | -83.61 |
| Dec 31, 2024 | 119.99 |
| Sep 30, 2024 | -16.01 |
| Jun 30, 2024 | -39.42 |
| Mar 31, 2024 | -35.71 |
| Dec 31, 2023 | 81.61 |
| Sep 30, 2023 | -33.71 |
| Jun 30, 2023 | -40.01 |
| Mar 31, 2023 | -56.39 |
| Dec 31, 2022 | 27.29 |
| Sep 30, 2022 | -64.65 |
| Jun 30, 2022 | -454.10 |
| Mar 31, 2022 | -404.06 |
| Dec 31, 2021 | 4,141.00 |
| Sep 30, 2021 | -4,961.00 |